Antonio Marchetti

Prof. Dr. Antonio Marchetti

Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
CMCarla Martella
Carla Martella
LFLara Felicioni
Lara Felicioni
FBFabio Barassi
Fabio Barassi
SSSimona Salvatore
Simona Salvatore
FBFiamma Buttitta
Fiamma Buttitta
Purpose: It has been reported that EGFR mutations in lung carcinomas make the disease more responsive to treatment with tyrosine kinase inhibitors. We decided to evaluate the prevalence of EGFR mutations in a large series of non–small-cell lung carcinomas (NSCLCs) and to develop a rapid and sensitive screening method. Patients and Methods: We examined 860 consecutive NSCLC patients for EGFR mutations in exons 18, 19, and 21 using a dual technical approach—direct sequencing of polymerase chain reaction (PCR) products and PCR single-strand conformation polymorphism (SSCP) analysis. Moreover, all lung adenocarcinomas were analyzed for K-ras mutations at codon 12 by allele-specific oligoprobe hybriditations. Results: There were no EGFR mutations in 454 squamous carcinomas and 31 large cell carcinomas investigated. Thirty-nine mutations were found in the series of 375 adenocarcinomas (10%). Mutations were present in 26% of 86 bronchioloalveolar carcinomas (BACs) and in 6% of 289 conventional lung adenocarcinomas; P = .000002. EGFR mutations and K-ras mutations were mutually exclusive. A multivariable analysis revealed that BAC histotype, being a never smoker, and female sex were independently associated with EGFR mutations (odds ratios: 4.542, 3.632, and 2.895, respectively). The SSCP analysis was accurate and sensitive, allowing identification of mutations that were undetectable (21% of cases) by direct sequencing. Conclusion: Mutations in the EGFR tyrosine kinase domain define a new molecular type of lung carcinoma, more frequent in particular subsets of patients. The SSCP assay is a rapid and reliable method for the detection of EGFR kinase domain mutations in lung cancer.

1 September 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
RCRiccardo Cazzoli
Riccardo Cazzoli
FBFiamma Buttitta
Fiamma Buttitta
Marta Di NicolaMarta Di Nicola
Marta Di Nicola
SMSara Malatesta
Sara Malatesta
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
HPHarvey Pass
Harvey Pass
Introduction: Lung cancer is the highest cause of mortality among tumor pathologies worldwide. There are no validated techniques for an early detection of pulmonary cancer lesions other than low-dose helical computed tomography scan. Unfortunately, this method has some negative effects. Recent studies have laid the basis for development of exosomes-based techniques to screen/diagnose lung cancers. As the isolation of circulating exosomes is a minimally invasive procedure, this technique opens new possibilities for diagnostic applications. Methods: We used a first set of 30 plasma samples from as many patients, including 10 patients affected by lung adenocarcinomas, 10 with lung granulomas, and 10 healthy smokers matched for age and sex as negative controls. Wide-range microRNAs analysis (742 microRNAs) was performed by quantitative real time polymerase chain reaction. Data were compared on the basis of lesion characteristics, using WEKA software for statistics and modeling. Subsequently, selected microRNAs were evaluated on an independent larger group of samples (105 specimens: 50 lung adenocarcinomas, 30 lung granulomas, and 25 healthy smokers). Results: This analysis led to the selection of four microRNAs to perform a screening test (miR-378a, miR-379, miR-139-5p, and miR-200b-5p), useful to divide population into two groups: nodule (lung adenocarcinomas + carcinomas) and non-nodule (healthy former smokers). Six microRNAs (miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100, and miR-154-3p) were selected for a second test on the nodule population to discriminate between lung adenocarcinoma and granuloma. Conclusions: The screening test showed 97.5% sensitivity, 72.0% specificity, and area under the curve receiver operating characteristic of 90.8%. The diagnostic test had 96.0% sensitivity, 60.0% specificity, and area under the curve receiver operating characteristic of 76.0%. Further evaluation is needed to confirm the predictive power of these models on larger cohorts of samples.

20 October 2006 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
FBFiamma Buttitta
Fiamma Buttitta
FBFabio Barassi
Fabio Barassi
GFGiuseppina Fresu
Giuseppina Fresu
LFLara Felicioni
Lara Felicioni
ACAntonio Chella
Antonio Chella
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
Activating mutations in the tyrosine kinase domain of the HER2 gene have recently been reported in lung adenocarcinomas, mainly in East Asian patients. Our study was devised to evaluate the prevalence and nature of HER2 mutations in lung adenocarcinomas from Caucasian patients. The mutational status of the HER2 gene was evaluated in 403 lung adenocarcinomas by PCR‐single strand conformation polymorphism analysis and direct sequencing of Exons 19 and 20. We found HER2 mutations in 9 (2.2%) cases. Seven (78%) of the mutations were in frame duplications/insertions at codons 776–779 (YVMA), the other 2 were base substitutions resulting in aminoacid changes. The hotspot mutation at bases 776–779 was previously found to be the most frequent HER2 mutation in Asiatic patients. The distribution of mutations was significantly different between conventional lung adenocarcinomas (CLAs) and lung adenocarcinomas with bronchioloalveolar features (ABAFs). Seven (6.2%) of 113 ABAFs and 2 (0.7%) of 290 CLA were mutated (p = 0.0025). In addition, the frequency of HER2 mutations was slightly higher in females (4.1%) than in males (1.8%) and in never smokers (3.1%) than in smokers (1.9%), but differences were not statistically significant. This series of tumors was also investigated for EGFR and K‐ras mutations. EGFR mutations were observed in 43 (10.7%) cases, and K‐ras mutations in 110 (27.3%) cases. EGFR, HER2 and K‐ras mutations were found to be mutually exclusive events. The presence of HER2 mutations in a subset of patients with lung adenocarcinoma raise hope to treat these patients with HER2 specific kinase inhibitors.

2 February 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
LFLara Felicioni
Lara Felicioni
FBFiamma Buttitta
Fiamma Buttitta
Recent reports have noted the presence of novel mutations of the epidermal growth factor receptor (EGFR) gene in small samples of DNA extracted from paraffin-embedded sections or laser-microdissected specimens.1,2 Nagahara et al.1 reported EGFR mutations in colon carcinomas. These mutations were novel G→A or A→G transitions. Similarly, Tsao et al. (July 14 issue)2 report that 24 (53 percent) of the mutations they found in specimens of non–small-cell lung cancers were novel variant mutations; 22 (92 percent) of these mutations were C→T/G→A or A→G/T→C transitions. These mutations had not been reported previously in more than 2000 analyses for EGFR mutations performed on DNA extracted from pieces of frozen tumors.

19 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Antonio MarchettiAntonio Marchetti
Antonio Marchetti
MGMaela Del Grammastro
Maela Del Grammastro
LFLara Felicioni
Lara Felicioni
SMSara Malatesta
Sara Malatesta
GFGiampaolo Filice
Giampaolo Filice
FBFiamma Buttitta
Fiamma Buttitta
Assessment of EGFR mutation in non-small cell lung cancer (NSCLC) patients is mandatory for optimization of pharmacologic treatment. In this respect, mutation analysis of circulating tumor cells (CTCs) may be desirable since they may provide real-time information on patient's disease status. Blood samples were collected from 37 patients enrolled in the TRIGGER study, a prospective phase II multi-center trial of erlotinib treatment in advanced NSCLC patients with activating EGFR mutations in tumor tissue. 10 CTC preparations from breast cancer patients without EGFR mutations in their primary tumors and 12 blood samples from healthy subjects were analyzed as negative controls. CTC preparations, obtained by the Veridex CellSearch System, were subjected to ultra-deep next generation sequencing (NGS) on the Roche 454 GS junior platform. CTCs fulfilling all Veridex criteria were present in 41% of the patients examined, ranging in number between 1 and 29. In addition to validated CTCs, potential neoplastic elements were seen in 33 cases. These included cells not fulfilling all Veridex criteria (also known as “suspicious objects”) found in 5 (13%) of 37 cases, and isolated or clustered large naked nuclei with irregular shape observed in 33 (89%) cases. EGFR mutations were identified by NGS in CTC preparations of 31 (84%) patients, corresponding to those present in matching tumor tissue. Twenty-five (96%) of 26 deletions at exon 19 and 6 (55%) of 11 mutations at exon 21 were detectable (P = 0.005). In 4 (13%) cases, multiple EGFR mutations, suggesting CTC heterogeneity, were documented. No mutations were found in control samples. We report for the first time that the CellSearch System coupled with NGS is a very sensitive and specific diagnostic tool for EGFR mutation analysis in CTC preparations with potential clinical impact.

13 December 2005 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
FBFiamma Buttitta
Fiamma Buttitta
LFLara Felicioni
Lara Felicioni
FBFabio Barassi
Fabio Barassi
CMCarla Martella
Carla Martella
DPDiego Paolizzi
Diego Paolizzi
Antonio MarchettiAntonio Marchetti
Antonio Marchetti